Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate virological efficacy and safety of two double
protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg
twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease
inhibitor naive HIV-1 patients.
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis